Benitec Grants License to RNAi Technology for Therapeutic Applications

Benitec said last week that it has granted the first license to use its DNA-directed RNAi technology for therapeutic applications to Revivicor.

According to Revivicor, it is a private firm spun out of PPL Therapeutics, and it focuses on “treatments for diabetes and whole organ transplantation, developed from the significant advances made in the fields of xenografts, stem cells, and tolerance technologies.”